Valuation: XORTX Therapeutics Inc.

Market Cap 3.09M 2.18M 1.92M 1.82M 1.65M 209M 3.12M 21.79M 8.4M 107M 8.17M 7.99M 343M P/E 2024
-0.98x
P/E 2025 -1x
Enterprise Value 2.26M 1.59M 1.41M 1.33M 1.21M 153M 2.28M 15.95M 6.15M 78.03M 5.98M 5.85M 251M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
98.47%
Yield 2024 *
-
Yield 2025 -
1 day-0.58%
1 week-8.60%
Current month-26.72%
1 month-27.29%
3 months-22.73%
6 months-10.31%
Current year-39.50%
1 week 1.69
Extreme 1.69
1.82
1 month 1.59
Extreme 1.5901
2.65
Current year 1.59
Extreme 1.5901
3.6
1 year 1.59
Extreme 1.5901
7.05
3 years 1.59
Extreme 1.5901
37.62
5 years 1.59
Extreme 1.5901
275.4
10 years 1.59
Extreme 1.5901
368.33
Manager TitleAgeSince
Chief Executive Officer 28 2026-06-14
Chief Executive Officer 66 2018-01-08
Director of Finance/CFO 62 2024-12-18
Director TitleAgeSince
Director/Board Member 66 2018-01-08
Director/Board Member 50 2026-03-23
Director/Board Member - 2026-03-23
Change 5-day change 1-year change 3-year change Capi.($)
-0.58%-8.60%-57.29%-93.70% 3.09M
-0.70%-4.28%+52.62%+86.42% 71.53B
+0.66%+2.18%+38.37%+82.87% 60.12B
+4.86%+6.16%+36.77%+26.10% 27.98B
-1.73%-4.30%-18.37%+357.94% 25.25B
-0.51%-2.28%+0.48%-9.27% 24.76B
+1.10%+1.88%+21.14%-4.46% 20.99B
+3.46%+3.02%+158.90%+337.81% 15.54B
+0.48%+0.86%+44.56%+168.42% 14.53B
+3.04%+0.66%-5.41%+518.58% 14.41B
Average +0.97%-1.57%+27.18%+147.07% 27.51B
Weighted average by Cap. +0.69%-1.52%+36.82%+130.05%

Financials

2024 2025
Net sales - -
Net income -3.31M -2.33M -2.06M -1.95M -1.77M -224M -3.35M -23.38M -9.01M -114M -8.76M -8.57M -368M -2.66M -1.87M -1.65M -1.56M -1.42M -180M -2.68M -18.74M -7.22M -91.68M -7.03M -6.87M -295M
Net Debt -2.43M -1.72M -1.51M -1.43M -1.3M -165M -2.46M -17.18M -6.62M -84.04M -6.44M -6.3M -270M -827K -583K -514K -487K -441K -55.91M -835K -5.84M -2.25M -28.55M -2.19M -2.14M -91.88M
Logo XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Employees
-
Date Price Change Volume
26-09-29 US$1.700 -0.58% 71,431
26-09-28 US$1.710 +1.18% 30,006
26-09-25 US$1.690 -1.74% 46,861
26-09-24 US$1.720 +1.18% 51,336
26-09-23 US$1.700 -8.60% 59,419

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XRTX Stock